REFERENCES
1. Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis. 2021;17:365-70.
2. Cholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2018;16:1356-8.
3. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790-800.
4. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249-53.
5. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972-8.
6. Bittermann T, Mahmud N, Weinberg EM, Reddy KR. Rising trend in waitlisting for alcoholic hepatitis with more favorable outcomes than other high model for end-stage liver disease in the current era. Transplantation. 2022;106:1401-10.
7. Battistella S, D'Arcangelo F, Grasso M, et al. Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management. Clin Mol Hepatol. 2023;29:S286-301.
8. Rice JP, Eickhoff J, Agni R, Ghufran A, Brahmbhatt R, Lucey MR. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl. 2013;19:1377-86.
9. Björnsson E, Olsson J, Rydell A, et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand J Gastroenterol. 2005;40:206-16.
10. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018;113:175-94.
11. Erard-Poinsot D, Dharancy S, Hilleret MN, et al. Natural history of recurrent alcohol-related cirrhosis after liver transplantation: fast and furious. Liver Transpl. 2020;26:25-33.
12. Kodali S, Kaif M, Tariq R, Singal AK. Alcohol relapse after liver transplantation for alcoholic cirrhosis-impact on liver graft and patient survival: a meta-analysis. Alcohol Alcohol. 2018;53:166-72.
13. Ntandja Wandji LC, Ningarhari M, Lassailly G, et al. Liver transplantation in alcohol-related liver disease and alcohol-related hepatitis. J Clin Exp Hepatol. 2023;13:127-38.
14. Chuncharunee L, Yamashiki N, Thakkinstian A, Sobhonslidsuk A. Alcohol relapse and its predictors after liver transplantation for alcoholic liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19:150.
15. Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl. 2008;14:159-72.
16. Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69:154-81.
17. Asrani SK, Trotter J, Lake J, et al. Meeting report: the dallas consensus conference on liver transplantation for alcohol associated hepatitis. Liver Transpl. 2020;26:950-1.
18. Lee YH, Jung KS, Kim SU, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008-2011). J Hepatol. 2015;63:486-93.
19. Arab JP, Izzy M, Leggio L, Bataller R, Shah VH. Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. Nat Rev Gastroenterol Hepatol. 2022;19:45-59.
20. Reus VI, Fochtmann LJ, Bukstein O, et al. The American psychiatric association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175:86-90.
21. Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014;77:315-23.
22. Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311:1889-900.
23. O'Malley SS, Zweben A, Fucito LM, et al. Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: a randomized clinical trial. JAMA Psychiatry. 2018;75:129-38.
24. Magistri P, Marzi L, Guerzoni S, et al. Impact of a multidisciplinary team on alcohol recidivism and survival after liver transplant for alcoholic disease. Transplant Proc. 2019;51:187-9.
25. National Center for Biotechnology Information. LiverTox: clinical and research information on drug-induced liver injury. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547852/. [Last accessed on 13 Dec 2024].
26. Morley KC, Baillie A, Fraser I, et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. Br J Psychiatry. 2018;212:362-9.
27. Berlakovich GA, Langer F, Freundorfer E, et al. General compliance after liver transplantation for alcoholic cirrhosis. Transpl Int. 2000;13:129-35.
28. Ehlers SL, Rodrigue JR, Widows MR, Reed AI, Nelson DR. Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research. Liver Transpl. 2004;10:412-7.
29. Pungpapong S, Manzarbeitia C, Ortiz J, et al. Cigarette smoking is associated with an increased incidence of vascular complications after liver transplantation. Liver Transpl. 2002;8:582-7.
30. Duerinckx N, Burkhalter H, Engberg SJ, et al; B-SERIOUS consortium. Correlates and outcomes of posttransplant smoking in solid organ transplant recipients: a systematic literature review and meta-analysis. Transplantation. 2016;100:2252-63.
31. Cheung A, Levitsky J. Follow-up of the post-liver transplantation patient: a primer for the practicing gastroenterologist. Clin Liver Dis. 2017;21:793-813.
32. Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl. 2002;8:482-7.
33. Schrem H, Kurok M, Kaltenborn A, et al. Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection. Liver Transpl. 2013;19:1252-61.
34. Coordes A, Albers AE, Lenarz M, et al. Incidence and long-term survival of patients with de novo head and neck carcinoma after liver transplantation. Head Neck. 2016;38:707-14.
35. Zhou J, Hu Z, Zhang Q, et al. Spectrum of de novo cancers and predictors in liver transplantation: analysis of the scientific registry of transplant recipients database. PLoS One. 2016;11:e0155179.
36. Tiwari A, Saigal S, Choudhary NS, et al. De novo malignancy after living donor liver transplantation: a large volume experience. J Clin Exp Hepatol. 2020;10:448-52.
37. Burra P, Senzolo M, Adam R, et al; ELITA, ELTR Liver Transplant Centers. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant. 2010;10:138-48.
38. Simo KA, Sereika S, Bitner N, Newton KN, Gerber DA. Medical epidemiology of patients surviving ten years after liver transplantation. Clin Transplant. 2011;25:360-7.
39. Marti-Aguado D, Clemente-Sanchez A, Bataller R. Cigarette smoking and liver diseases. J Hepatol. 2022;77:191-205.
40. Vanlerberghe BTK, van Malenstein H, Sainz-Barriga M, et al. Tacrolimus drug exposure level and smoking are modifiable risk factors for early de novo malignancy after liver transplantation for alcohol-related liver disease. Transpl Int. 2024;37:12055.
41. Singh A, De A, Singh V. Post-transplant malignancies in alcoholic liver disease. Transl Gastroenterol Hepatol. 2020;5:30.
42. Izzy M, Fortune BE, Serper M, et al. Management of cardiac diseases in liver transplant recipients: comprehensive review and multidisciplinary practice-based recommendations. Am J Transplant. 2022;22:2740-58.
43. Spengler EK, O'Leary JG, Te HS, et al. Liver transplantation in the obese cirrhotic patient. Transplantation. 2017;101:2288-96.
44. Dare AJ, Plank LD, Phillips AR, et al. Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation. Liver Transpl. 2014;20:281-90.
45. D'Avola D, Cuervas-Mons V, Martí J, et al. Cardiovascular morbidity and mortality after liver transplantation: the protective role of mycophenolate mofetil. Liver Transpl. 2017;23:498-509.
46. VanWagner LB, Serper M, Kang R, et al. Factors associated with major adverse cardiovascular events after liver transplantation among a national sample. Am J Transplant. 2016;16:2684-94.
47. Targher G, Bertolini L, Chonchol M, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia. 2010;53:1341-8.
48. Houlihan DD, Armstrong MJ, Davidov Y, et al. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens? Liver Transpl. 2011;17:1292-8.
49. Fussner LA, Charlton MR, Heimbach JK, et al. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int. 2014;34:1259-66.
50. Mehtani R, Saigal S. Long term complications of immunosuppression post liver transplant. J Clin Exp Hepatol. 2023;13:1103-15.
51. Taneja S, Roy A. Nonalcoholic steatohepatitis recurrence after liver transplant. Transl Gastroenterol Hepatol. 2020;5:24.
52. Choudhary NS, Saigal S. Preventive strategies for nonalcoholic fatty liver disease after liver transplantation. J Clin Exp Hepatol. 2019;9:619-24.
53. Bhati C, Idowu MO, Sanyal AJ, et al. Long-term outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis-related cirrhosis. Transplantation. 2017;101:1867-74.
54. Shetty A, Giron F, Divatia MK, Ahmad MI, Kodali S, Victor D. Nonalcoholic fatty liver disease after liver transplant. J Clin Transl Hepatol. 2021;9:428-35.
55. Poudel S, Gupta S, Saigal S. Basics and art of immunosuppression in liver transplantation. J Clin Exp Hepatol. 2024;14:101345.
56. Azhie A, Sheth P, Hammad A, Woo M, Bhat M. Metabolic complications in liver transplantation recipients: how we can optimize long-term survival. Liver Transpl. 2021;27:1468-78.
57. Rinella ME, Satapathy SK, Brandman D, et al. Factors impacting survival in those transplanted for NASH Cirrhosis: data from the NailNASH consortium. Clin Gastroenterol Hepatol. 2023;21:445-455.e2.
58. VanWagner LB, Holl JL, Montag S, et al. Blood pressure control according to clinical practice guidelines is associated with decreased mortality and cardiovascular events among liver transplant recipients. Am J Transplant. 2020;20:797-807.
59. Neuberger JM, Mamelok RD, Neuhaus P, et al; ReSpECT Study Group. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘ReSpECT’ study. Am J Transplant. 2009;9:327-36.
60. Gabrielli F, Golfieri L, Nascimbeni F, Andreone P, Gitto S. Metabolic disorders in liver transplant recipients: the state of the art. J Clin Med. 2024;13:1014.
61. Lemos BO, Silva RCMA, Silva RFD. Prevalence and time of development of systemic arterial hypertension in patients after liver transplantation. Arq Gastroenterol. 2021;58:77-81.
62. Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American association for the study of liver diseases and the american society of transplantation. Liver Transpl. 2013;19:3-26.
63. Di Stefano C, Vanni E, Mirabella S, et al. Risk factors for arterial hypertension after liver transplantation. J Am Soc Hypertens. 2018;12:220-9.
64. Paklar N, Mijic M, Filipec-Kanizaj T. The outcomes of liver transplantation in severe metabolic dysfunction-associated steatotic liver disease patients. Biomedicines. 2023;11:3096.
65. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010;16:431-9.
66. Narayanan P, Mara K, Izzy M, et al. Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation. Transplantation. 2019;103:e14-21.
67. Kwong AJ, Devuni D, Wang C, et al; Re-Evaluating Age Limits in Transplantation (REALT) Consortium. Outcomes of liver transplantation among older recipients with nonalcoholic steatohepatitis in a large multicenter US cohort: the re-evaluating age limits in transplantation consortium. Liver Transpl. 2020;26:1492-503.
68. Gitto S, Golfieri L, Gabrielli F, et al; MEDITRA Research Group. Physical activity in liver transplant recipients: a large multicenter study. Intern Emerg Med. 2024;19:343-52.
